CCM
TGTX icon

Copernicus Capital Management’s TG Therapeutics TGTX Stock Holding History

Copernicus Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,000
Closed -$337K – 19
2021
Q1 		$337K Buy
7,000
+1,153
+20% +$55.4K 5.45% 9
2020
Q4 		$304K Sell
5,847
-89,153
-94% -$3.01M 4.74% 10
2020
Q3 		$2.54M Buy
+95,000
New +$2.19M 2.42% 15

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Copernicus Capital Management's TGTX Position: Q2 2021 in Review

Copernicus Capital Management sold out of TG Therapeutics (TGTX) in Q2 2021, closing a stake of 7,000 shares — an estimated $337K sold.

Copernicus Capital Management first reported a position in TGTX in Q3 2020 and held it in 3 quarters. The position peaked at $2.54M in Q3 2020. 237 funds tracked by Wall St. Rank hold TGTX as of Q2 2021.

  • Copernicus Capital Management reported no remaining TG Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Copernicus Capital Management sold 7,000 TG Therapeutics shares in Q2 2021, an estimated $337K.
  • Copernicus Capital Management first reported a position in TG Therapeutics in Q3 2020 and held it in 3 quarters.
  • Copernicus Capital Management's TG Therapeutics position peaked at $2.54M in Q3 2020.
  • 237 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2021.

Based on Copernicus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.